Is monocyte HLA-DR expression monitoring a useful tool to predict the risk of secondary infection?

Minerva Anestesiologica

Volumn 76, Issue 9, 2010, Pages 737-744

  Lukaszewicz, A C ^a   Faivre, V ^a   Payen, D ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Cross infection; Immunity; Major histocompatibility complex; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; HYDROCORTISONE; IMMUNOMODULATING AGENT; IMMUNOSTIMULATING AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CRITICALLY ILL PATIENT; DOWN REGULATION; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL MONITORING; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTION CONTROL; INFECTION RISK; INNATE IMMUNITY; LUNG DISEASE; MONOCYTE; NONHUMAN; PREDICTION; PSEUDOMONAS INFECTION; RECURRENT INFECTION; REVIEW; RISK ASSESSMENT; SECONDARY INFECTION; SEPSIS;

CROSS INFECTION; HLA-DR ANTIGENS; HUMANS; MONOCYTES; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 77957940340     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Adib-Conquy M, Cavaillon JM. Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS 2007; 581:3723-3733.
2. Lukaszewicz AC, Payen D. Similarities of clinical aspects of sepsis and non-infectious SIRS. In: Cavaillon JM, Adrie C, editors. Weinheim: Wiley-VHC Verlag GmbH & Co. KGaA; 2008. p. 41-56.
3. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8:279-289.
4. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001;163:316-321.
5. Lukaszewicz AC, Grienay M, Resche-Rigon M, Pirracchio R, Faivre V, Boval B et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 2009;37:2746-2752.
6. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006;32:1175-1183.
7. Payen D, Faivre V, Lukaszewicz AC, Villa F, Goldberg P. Expression of monocyte human leukocyte antigen-DR in relation with sepsis severity and plasma mediators. Minerva Anestesiol 2009;75:484-493.
8. Hershman MJ, Cheadle WG, Wellhausen SR, Davidson PF, Polk HC Jr. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 1990;77:204-207.
9. Allen ML, Peters MJ, Goldman A, Elliott M, James I, Callard R et al. Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care. Crit Care Med 2002;30:1140-1145.
10. Cheadle WG, Hershman MJ, Wellhausen SR, Polk HC Jr. HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. Am J Surg 1991;161:639-645.
11. Wakefield CH, Carey PD, Foulds S, Monson JR, Guillou PJ. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg 1993;80:205-209.
12. Venet F, Tissot S, Debard AL, Faudot C, Crampe C, Pachot A et al. Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock. Crit Care Med 2007;35:1910-1917.
13. Christou NV, Meakins JL, Gordon J, Yee J, Hassan-Zahraee M, Nohr CW et al. The delayed hypersensitivity response and host resistance in surgical patients. 20 years later. Ann Surg 1995; 222: 534-546; discussion 46-48.
14. Marie C, Fitting C, Muret J, Payen D, Cavaillon JM. Interleukin 8 production in whole blood assays: Is interleukin 10 responsible for the downregulation observed in sepsis? Cytokine 2000; 12: 55-61.
15. Marie C, Muret J, Fitting C, Losser MR, Payen D, Cavaillon JM. Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. Blood 1998;91:3439-3446.
16. Marie C, Muret J, Fitting C, Payen D, Cavaillon JM. Interleukin-1 receptor antagonist production during infectious and noninfectious systemic inflammatory response syndrome. Crit Care Med 2000;28:2277-2282.
17. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747-1754.
18. Wolk K, Docke WD, von Baehr V, Volk HD, Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 2000;96:218-223.
19. Wolk K, Kunz S, Crompton NE, Volk HD, Sabat R. Multiple mechanisms of reduced major histocompatibility complex class II expression in endotoxin tolerance. J Biol Chem 2003;278:18030-18036.
20. Adib-Conquy M, Moine P, Asehnoune K, Edouard A, Espevik T, Miyake K et al. Toll-like receptor-mediated tumor necrosis factor and interleukin-10 production differ during systemic inflammation. Am J Respir Crit Care Med 2003;168:158-164.
21. Boldrick JC, Alizadeh AA, Diehn M, Dudoit S, Liu CL, Belcher CE et al. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci USA 2002;99:972-977.
22. Cavaillon JM, Adrie C, Fitting C, Adib-Conquy M. Reprogramming of circulatory cells in sepsis and SIRS. J Endotoxin Res 2005;11:311-320.
23. Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 2002;166:1475-1482.
24. Payen D, Lukaszewicz AC, Belikova I, Faivre V, Gelin C, Russwurm S et al. Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med 2008;34:1371-1376.
25. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001;166:6952-6963.
26. Adib-Conquy M, Adrie C, Fitting C, Gattolliat O, Beyaert R, Cavaillon JM. Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients. Crit Care Med 2006;34:2377-2385.
27. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009;101:36-47.
28. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-243.
29. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-140.
30. Garrouste Orgeas M, Timsit JF, Soufir L, Tafflet M, Adrie C, Philippart F et al. Impact of adverse events on outcomes in intensive care unit patients. Crit Care Med 2008;36:2041-2047.
31. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002;28:108-121.
32. Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004;30:580-588.
33. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997;3:678-681.
34. Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 2003;29:646-651.
35. Schneider C, von Aulock S, Zedler S, Schinkel C, Hartung T, Faist E. Perioperative recombinant human granulocyte colonystimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg 2004;239:75-81.
36. Carr R, Brocklehurst P, Dore CJ, Modi N. Granulocytemacrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a singleblind, multicentre, randomised controlled trial. Lancet 2009;373:226-233.
37. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009;180:640-648.
38. Meropol NJ, Rustum YM, Creaven PJ, Blumenson LE, Frank C. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential rolefor growth factor as mucosal protectant. Cancer Invest 1999; 17:1-9.
39. Faivre V, Lukaszewicz AC, Alves A, Charron D, Payen D, Haziot A. Accelerated in vitro differentiation of blood monocytes into dendritic cells in human sepsis. Clin Exp Immunol 2007;147:426-39.
40. Docke WD, Hoflich C, Davis KA, Rottgers K, Meisel C, Kiefer P et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 2005;51:2341-2347.
41. Friese MA, Jones EY, Fugger L. MHC II molecules in inflammatory diseases: interplay of qualities and quantities. Trends Immunol 2005;26:559-61.
42. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell 2002;109(Suppl):S21-S33.
43. Fernandez EM, O'Toole PJ, Morrison IE, Cherry RJ, Fernandez N. Interaction of HLA-DR with actin microfilaments. Hum Immunol 2003;64:327-337.
44. Huang D, Cai DT, Chua RY, Kemeny DM, Wong SH. Nitricoxide synthase 2 interacts with CD74 and inhibits its cleavage by caspase during dendritic cell development. J Biol Chem 2008;283:1713-1722.
45. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 2001;19:331-373.
46. Caille V, Chiche JD, Nciri N, Berton C, Gibot S, Boval B et al. Histocompatibility leukocyte antigen-D related expression is specifically altered and predicts mortality in septic shock but not in other causes of shock. Shock 2004;22:521-526.
47. Satoh A, Miura T, Satoh K, Masamune A, Yamagiwa T, Sakai Y et al. Human leukocyte antigen-DR expression on peripheral monocytes as a predictive marker of sepsis during acute pancreatitis. Pancreas 2002;25:245-250.
48. Asadullah K, Woiciechowsky C, Docke WD, Liebenthal C, Wauer H, Kox W et al. Immunodepression following neurosurgical procedures. Crit Care Med 1995;23:1976-1983.
49. Woiciechowsky C, Asadullah K, Nestler D, Eberhardt B, Platzer C, Schoning B et al. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med 1998;4:808-813.
50. Hynninen M, Pettila V, Takkunen O, Orko R, Jansson SE, Kuusela P et al.: Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock 2003;20:1-4.
51. Monneret G, Finck ME, Venet F, Debard AL, Bohe J, Bienvenu J et al. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett 2004;95:193-198.
52. Polk HC Jr, Cheadle WG, Livingston DH, Rodriguez JL, Starko KM, Izu AE et al. A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am J Surg 1992;163:191-196.
53. van den Berk JM, Oldenburger RH, van den Berg AP, Klompmaker IJ, Mesander G, van Son WJ et al. Low HLADR expression on monocytes as a prognostic marker for bacterial sepsis after liver transplantation. Transplantation 1997;63:1846-1848.